Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 6

See more details

Referenced in 3 patents
65 readers on Mendeley
  • Article usage
  • Citations to this article (304)

Advertisement

Research Article Free access | 10.1172/JCI2881

In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1.

L Guedez, W G Stetler-Stevenson, L Wolff, J Wang, P Fukushima, A Mansoor, and M Stetler-Stevenson

Flow Cytometry Unit, Hematopathology Section, National Cancer Institute, Bethesda, MD 20892-1500, USA.

Find articles by Guedez, L. in: PubMed | Google Scholar

Flow Cytometry Unit, Hematopathology Section, National Cancer Institute, Bethesda, MD 20892-1500, USA.

Find articles by Stetler-Stevenson, W. in: PubMed | Google Scholar

Flow Cytometry Unit, Hematopathology Section, National Cancer Institute, Bethesda, MD 20892-1500, USA.

Find articles by Wolff, L. in: PubMed | Google Scholar

Flow Cytometry Unit, Hematopathology Section, National Cancer Institute, Bethesda, MD 20892-1500, USA.

Find articles by Wang, J. in: PubMed | Google Scholar

Flow Cytometry Unit, Hematopathology Section, National Cancer Institute, Bethesda, MD 20892-1500, USA.

Find articles by Fukushima, P. in: PubMed | Google Scholar

Flow Cytometry Unit, Hematopathology Section, National Cancer Institute, Bethesda, MD 20892-1500, USA.

Find articles by Mansoor, A. in: PubMed | Google Scholar

Flow Cytometry Unit, Hematopathology Section, National Cancer Institute, Bethesda, MD 20892-1500, USA.

Find articles by Stetler-Stevenson, M. in: PubMed | Google Scholar

Published December 1, 1998 - More info

Published in Volume 102, Issue 11 on December 1, 1998
J Clin Invest. 1998;102(11):2002–2010. https://doi.org/10.1172/JCI2881.
© 1998 The American Society for Clinical Investigation
Published December 1, 1998 - Version history
View PDF
Abstract

Cellular pathways for induction of programmed cell death (PCD) have been identified, but little is known about specific extracellular matrix processes that may affect apoptosis along those pathways. In this study, a series of Burkitt's lymphoma (BL) cell lines were assayed for their expression of tissue inhibitor of metalloproteinases (TIMP)-1. Results indicate that TIMP-1-positive BL lines show resistance to cold-shock-induced apoptosis. Furthermore, recombinant TIMP-1, but not TIMP-2 or a synthetic metalloproteinase inhibitor (BB-94), confers resistance to apoptosis induced by both CD95-dependent and -independent (cold shock, serum deprivation, and gamma-radiation) pathways in TIMP-1-negative BL lines. TIMP-1 suppression of PCD is not due to metalloproteinase inhibition, as reduction and alkylation of the TIMP-1 did not abolish this activity. Retroviral induction of TIMP-1 not only resulted in cell survival but also in continued DNA synthesis for up to 5 d in the absence of serum, while controls underwent apoptosis. This resistance to apoptosis is reversed by anti-TIMP-1 antibodies, demonstrating that secreted TIMP-1 is active in blocking apoptosis. Furthermore, TIMP-1 upregulation induced expression of Bcl-XL but not Bcl-2 as well as decreased NF-kappaB activity as compared with controls. These results demonstrate that TIMP-1 suppresses apoptosis in B cells and suggests a novel activity for TIMP-1 in tissue homeostasis.

Version history
  • Version 1 (December 1, 1998): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 6
  • Article usage
  • Citations to this article (304)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 3 patents
65 readers on Mendeley
See more details